RU2013151904A - Применение соединений мышьяка для лечения отторжения ткани или органа - Google Patents
Применение соединений мышьяка для лечения отторжения ткани или органа Download PDFInfo
- Publication number
- RU2013151904A RU2013151904A RU2013151904/15A RU2013151904A RU2013151904A RU 2013151904 A RU2013151904 A RU 2013151904A RU 2013151904/15 A RU2013151904/15 A RU 2013151904/15A RU 2013151904 A RU2013151904 A RU 2013151904A RU 2013151904 A RU2013151904 A RU 2013151904A
- Authority
- RU
- Russia
- Prior art keywords
- tissue
- sodium meta
- meta arsenite
- treatment
- kit
- Prior art date
Links
- 150000001495 arsenic compounds Chemical class 0.000 title 1
- 229940093920 gynecological arsenic compound Drugs 0.000 title 1
- 210000000056 organ Anatomy 0.000 claims abstract 8
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 claims abstract 8
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
Abstract
1. Применение метаарсенита натрия в производстве фармацевтической композиции для лечения отторжения ткани или органа.2. Применение по п. 1, где отторжение ткани или органа связано с реакцией "хозяин против трансплантата".3. Применение по п. 1 или 2, где метаарсенит натрия составлен для орального введения.4. Набор для лечения отторжения ткани или органа, включающий по меньшей мере одну дозу метаарсенита натрия.5. Набор по п. 4, где отторжение ткани или органа связано с реакцией "хозяин против трансплантата".6. Набор по п. 4 или 5, где метаарсенит натрия составлен для орального введения.
Claims (6)
1. Применение метаарсенита натрия в производстве фармацевтической композиции для лечения отторжения ткани или органа.
2. Применение по п. 1, где отторжение ткани или органа связано с реакцией "хозяин против трансплантата".
3. Применение по п. 1 или 2, где метаарсенит натрия составлен для орального введения.
4. Набор для лечения отторжения ткани или органа, включающий по меньшей мере одну дозу метаарсенита натрия.
5. Набор по п. 4, где отторжение ткани или органа связано с реакцией "хозяин против трансплантата".
6. Набор по п. 4 или 5, где метаарсенит натрия составлен для орального введения.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89900707P | 2007-02-02 | 2007-02-02 | |
| US60/899,007 | 2007-02-02 | ||
| US12/068,006 US8945505B2 (en) | 2007-02-02 | 2008-01-31 | Use of arsenic compounds for treatment of pain and inflammation |
| US12/068,006 | 2008-01-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012134218A Division RU2630574C2 (ru) | 2007-02-02 | 2008-02-01 | Применение соединений мышьяка для лечения боли и воспаления |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013151904A true RU2013151904A (ru) | 2015-05-27 |
| RU2665362C2 RU2665362C2 (ru) | 2018-08-29 |
Family
ID=39322911
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012134218A RU2630574C2 (ru) | 2007-02-02 | 2008-02-01 | Применение соединений мышьяка для лечения боли и воспаления |
| RU2009132951/15A RU2468806C2 (ru) | 2007-02-02 | 2008-02-01 | Применение соединений мышьяка для лечения боли и воспаления |
| RU2013151904A RU2665362C2 (ru) | 2007-02-02 | 2013-11-21 | Применение соединений мышьяка для лечения отторжения ткани или органа |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012134218A RU2630574C2 (ru) | 2007-02-02 | 2008-02-01 | Применение соединений мышьяка для лечения боли и воспаления |
| RU2009132951/15A RU2468806C2 (ru) | 2007-02-02 | 2008-02-01 | Применение соединений мышьяка для лечения боли и воспаления |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8945505B2 (ru) |
| EP (1) | EP2114419B8 (ru) |
| JP (3) | JP5411709B2 (ru) |
| KR (1) | KR101479519B1 (ru) |
| CN (2) | CN103550253A (ru) |
| AR (1) | AR065138A1 (ru) |
| AU (1) | AU2008214084C9 (ru) |
| BR (1) | BRPI0807154B8 (ru) |
| CA (3) | CA2845292C (ru) |
| DK (1) | DK2114419T3 (ru) |
| ES (1) | ES2460868T3 (ru) |
| IL (3) | IL200173A (ru) |
| MX (1) | MX2009008174A (ru) |
| NZ (1) | NZ578621A (ru) |
| PL (1) | PL2114419T3 (ru) |
| RU (3) | RU2630574C2 (ru) |
| TW (1) | TWI404538B (ru) |
| WO (1) | WO2008097824A2 (ru) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090061022A1 (en) * | 2004-10-08 | 2009-03-05 | Sang Bong Lee | Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US8045505B2 (en) * | 2007-01-18 | 2011-10-25 | Science Applications International Corporation | Mechanism for automatic network formation and medium access coordination |
| WO2009109911A1 (en) | 2008-03-04 | 2009-09-11 | Pfizer Limited | Methods of treating chronic pain |
| CN102427822A (zh) * | 2009-05-18 | 2012-04-25 | 香港大学 | 治疗炎症性关节炎的组合物和方法 |
| IN2012DN02521A (ru) | 2009-08-28 | 2015-08-28 | Rinat Neuroscience Corp | |
| WO2011031890A2 (en) * | 2009-09-10 | 2011-03-17 | Kominox Usa, Inc. | Cancer stem cell-targeted and drug resistant cancer therapy |
| FR3004949B1 (fr) * | 2013-04-26 | 2016-02-05 | Centre Nat Rech Scient | Traitement de maladies autoimmunes et inflammatoires par les composes de l'arsenic as203 et/ou as205 administres par voie locale |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| US9896502B2 (en) | 2014-03-21 | 2018-02-20 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| KR102015858B1 (ko) * | 2015-10-23 | 2019-08-30 | 손영태 | 법제된 비상을 함유하는 면역력 증강을 위한 약학적 조성물 |
| WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| KR101834366B1 (ko) * | 2016-11-21 | 2018-03-05 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
| KR101844049B1 (ko) * | 2016-12-05 | 2018-03-30 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물 |
| KR101844050B1 (ko) | 2016-12-09 | 2018-05-14 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물 |
| CN106890353A (zh) * | 2017-03-31 | 2017-06-27 | 应剑波 | 一种具有抗菌滋养功能的医用辅料 |
| US10716807B2 (en) * | 2017-05-09 | 2020-07-21 | Medsenic | Method of treating relapsing-remitting multiple sclerosis using arsenic trioxide |
| CA3094115A1 (en) * | 2018-03-22 | 2019-09-26 | Komipharm International Australia Pty Ltd | Pharmaceutical composition comprising meta arsenite and method of manufacture |
| RU2687599C1 (ru) * | 2018-11-22 | 2019-05-15 | Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) | Способ лечения постмастэктомического синдрома |
| CN109674817B (zh) * | 2019-01-31 | 2021-06-29 | 哈尔滨医科大学 | 三氧化二砷在制备治疗晚期动脉粥样硬化药物中的用途 |
| ES2952205T3 (es) * | 2019-05-21 | 2023-10-30 | Medsenic | Uso de iones de cobre para potenciar los efectos terapéuticos del arsénico |
| AU2021219576A1 (en) * | 2020-02-16 | 2022-09-15 | Komipharm International Australia Pty Ltd | Method of treatment using meta-arsenite |
| RU2755329C2 (ru) * | 2020-03-13 | 2021-09-15 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ИМЕНИ АКАДЕМИКА А.М. ГРАНОВА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ /ФГБУ "РНЦРХТ им. академика А.М. Гранова" Минздрава России | Способ лечения нерезектабельной гилюсной холангиокарциномы |
| EP4125863A1 (en) * | 2020-04-03 | 2023-02-08 | Medsenic | Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animals |
| EP3988093A1 (en) * | 2020-10-22 | 2022-04-27 | Medsenic | Use of an arsenic compound for treating a cytokine storm |
| KR102240693B1 (ko) * | 2020-05-18 | 2021-04-15 | 주식회사 케마스 | 육산화사비소를 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학조성물 |
| KR20220020637A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물 |
| KR20220020633A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 탈모방지 또는 발모촉진용 주사제 조성물 |
| WO2022133246A1 (en) | 2020-12-17 | 2022-06-23 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US536273A (en) * | 1895-03-26 | Tavus rein | ||
| US1498639A (en) * | 1919-12-02 | 1924-06-24 | David S Pratt | Arsenical composition and method of making same |
| US3622664A (en) * | 1968-11-21 | 1971-11-23 | John A Brown | Treatment of infectious keratitis in animals with sodium arsenite |
| SU955909A1 (ru) * | 1980-06-25 | 1982-09-07 | Центральный Ордена Ленина Институт Усовершенствования Врачей | Способ профилактики осложнений при пересадке тканей |
| US4677974A (en) * | 1985-09-30 | 1987-07-07 | David Leonardi | Method and apparatus for immobilizing an eyelid |
| AU647822B2 (en) | 1990-09-14 | 1994-03-31 | Marion Merrell Dow Inc. | Novel carbocyclic adenosine analogs useful as immunosuppressants |
| ITTO930510A1 (it) | 1993-07-09 | 1993-10-07 | Walter Tarello | Farmaci attivi contro la chronic fatigue syndrome (c.f.s.) |
| WO1995022336A1 (en) | 1994-02-18 | 1995-08-24 | Tamara Vasilievna Vorobieva | Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system |
| US5362735A (en) * | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
| IT1272994B (it) * | 1994-05-25 | 1997-07-01 | Giampiero Valletta | Uso di prodotti contenenti magnesio nella terapia e nella profilassi di malattie neoplastiche e di malattie di tipo autoimmunitario.- |
| IT1295067B1 (it) * | 1997-09-25 | 1999-04-27 | Walter Tarello | Uso di arsenico per preparare un medicamento per il trattamento della sindrome premestruale |
| ATE407683T1 (de) | 1997-10-15 | 2008-09-15 | Polarx Biopharmaceuticals Inc | Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von multiplen myelom |
| KR20020083678A (ko) * | 2001-04-28 | 2002-11-04 | 주식회사 한국미생물연구소 | 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물 |
| TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| TWI259079B (en) * | 2002-02-08 | 2006-08-01 | Merck & Co Inc | N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives |
| CA2481602C (en) | 2002-04-10 | 2011-06-21 | Korea Microbiological Laboratories, Ltd. | Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| RU2310460C2 (ru) * | 2002-04-10 | 2007-11-20 | Корея Микробиолоджикал Лабораторис, Лтд. | Фармацевтическая композиция для лечения злокачественной опухоли, содержащая арсенит натрия |
| FR2838965B1 (fr) * | 2002-04-26 | 2004-06-25 | Centre Nat Rech Scient | Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme |
| JP2005206591A (ja) * | 2003-12-25 | 2005-08-04 | Mitsubishi Pharma Corp | 神経因性疼痛の予防及び／又は治療のための医薬 |
| WO2006069293A2 (en) * | 2004-12-22 | 2006-06-29 | Friedman Robert S | Composition comprising n-acetylcysteine and further pain or anti- inflamm medications |
| JP2006206461A (ja) | 2005-01-26 | 2006-08-10 | Teizo Chinen | アレルギー疾患の予防・治療用組成物 |
| WO2006104292A1 (en) * | 2005-03-31 | 2006-10-05 | Komipharm International Co., Ltd. | Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts |
| EP1721615A1 (en) * | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US20060292243A1 (en) * | 2005-06-24 | 2006-12-28 | Shao-Chi Hsin | Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases |
-
2008
- 2008-01-31 US US12/068,006 patent/US8945505B2/en active Active
- 2008-02-01 JP JP2009548463A patent/JP5411709B2/ja not_active Expired - Fee Related
- 2008-02-01 EP EP08714162.8A patent/EP2114419B8/en active Active
- 2008-02-01 AR ARP080100429A patent/AR065138A1/es unknown
- 2008-02-01 RU RU2012134218A patent/RU2630574C2/ru active
- 2008-02-01 AU AU2008214084A patent/AU2008214084C9/en not_active Ceased
- 2008-02-01 NZ NZ578621A patent/NZ578621A/en not_active IP Right Cessation
- 2008-02-01 PL PL08714162T patent/PL2114419T3/pl unknown
- 2008-02-01 WO PCT/US2008/052751 patent/WO2008097824A2/en not_active Ceased
- 2008-02-01 CA CA2845292A patent/CA2845292C/en active Active
- 2008-02-01 ES ES08714162.8T patent/ES2460868T3/es active Active
- 2008-02-01 RU RU2009132951/15A patent/RU2468806C2/ru active
- 2008-02-01 CA CA2845299A patent/CA2845299C/en active Active
- 2008-02-01 BR BRPI0807154A patent/BRPI0807154B8/pt not_active IP Right Cessation
- 2008-02-01 CN CN201310522816.6A patent/CN103550253A/zh active Pending
- 2008-02-01 KR KR1020097018389A patent/KR101479519B1/ko not_active Expired - Fee Related
- 2008-02-01 CN CN200880003873A patent/CN101641105A/zh active Pending
- 2008-02-01 TW TW097104110A patent/TWI404538B/zh active
- 2008-02-01 CA CA2677388A patent/CA2677388C/en active Active
- 2008-02-01 DK DK08714162.8T patent/DK2114419T3/da active
- 2008-02-01 MX MX2009008174A patent/MX2009008174A/es active IP Right Grant
-
2009
- 2009-07-30 IL IL200173A patent/IL200173A/en active IP Right Grant
-
2012
- 2012-02-02 IL IL217891A patent/IL217891A/en not_active IP Right Cessation
-
2013
- 2013-04-24 US US13/869,911 patent/US10058570B2/en active Active
- 2013-05-07 JP JP2013097681A patent/JP5825611B2/ja not_active Expired - Fee Related
- 2013-11-05 IL IL229255A patent/IL229255A/en active IP Right Grant
- 2013-11-21 RU RU2013151904A patent/RU2665362C2/ru active
-
2014
- 2014-10-14 JP JP2014209816A patent/JP5853347B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013151904A (ru) | Применение соединений мышьяка для лечения отторжения ткани или органа | |
| EA201000105A1 (ru) | Химические соединения | |
| MX2009008439A (es) | Nuevos inhibidores de la replicacion del virus de hepatitis c. | |
| EA200800172A1 (ru) | 2,4-диаминопиримидины как ингибиторы aurora | |
| EA201070544A1 (ru) | Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений | |
| BRPI0720551A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| CU23743B7 (es) | Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematológicas | |
| CY1110900T1 (el) | Χημικες ενωσεις | |
| CY1108275T1 (el) | Χημικες ενωσεις | |
| TW200640908A (en) | Chemical compounds | |
| UY30809A1 (es) | Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones | |
| EA201100447A1 (ru) | Органические соединения | |
| BRPI0914902B8 (pt) | Composição farmacêutica para uso no tratamento de mal de parkinson | |
| EA201100921A1 (ru) | Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ | |
| EA201100255A1 (ru) | 5-алкинилпиримидины | |
| EA200801997A1 (ru) | Новые соединения | |
| MX2010001020A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas. | |
| SE0401970D0 (sv) | Novel compounds | |
| EA201100254A1 (ru) | Новые соединения | |
| MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
| SE0401969D0 (sv) | Piperidine derivatives | |
| MX2010009756A (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos. | |
| CL2004000979A1 (es) | Nonapeptidos acilados tipo lysobacitina, composicion que los contiene metodo de preparacion, util como bactericida. | |
| BRPI0610907A2 (pt) | composto ou precursores hidrolisÁveis in vivo ou sal farmaceuticamente aceitÁvel do mesmo, mÉtodos de tratamento ou profilaxia de uma doenÇa ou condiÇço na qual a modulaÇço do receptor de mch1 É benÉfica e de tratamento ou profilaxia de doenÇas, composiÇço farmacÊutica, e, uso de um composto | |
| DK1809288T3 (da) | Anvendelse af 1,4-bis-(3-aminoalkyl)piperazinderivater ved behandling af neurodegenerative sygdomme |